Industry vet Alfonso Quintas-Cardama named new CMO of Foghorn

8 August 2023

US cancer-focused biotech Foghorn Therapeutics (Nasdaq: FHTX) today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023.

Foghorn’s current CMO, Dr Sam Agresta, will simultaneously retire from the company on September 11, 2023, but will provide consulting services through early January 2024.

Dr Quintás-Cardama most recently was the CMO at TCR2 since 2017, where he led the development of the company’s cell therapy platform. Dr Quintás-Cardama’s prior experience includes a role as the head of clinical development for cell therapies at GSK (LSE: GSK), where he was instrumental in building GSK’s cell therapies unit, and as the global clinical leader at Novartis (NOVN: VX) from 2014 to 2016, where he led the development of Kymriah (tisagenlecleucel), the first FDA-approved CAR-T cell therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK